Wall Street was sorting through two batches of news from Jasper Therapeutics Inc., which made public positive data from the phase Ib study called Etesian with KIT-targeting briquilimab in adults with allergic asthma, while making known the outcome of a probe into the phase Ib/II Beacon study with the same drug in chronic spontaneous urticaria.
China’s National Medical Products Administration gave the nod to Innovent Biologics Inc.’s picankibart (IBI-112), branded as Pecondle, for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
The priority BLA from Otsuka Pharmaceutical Co. Ltd., of Tokyo, and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization Inc., for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN) has received accelerated approved by the U.S. FDA.
China’s National Medical Products Administration gave the nod to Innovent Biologics Inc.’s picankibart (IBI-112), branded as Pecondle, for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
CSPC Pharmaceutical Group Ltd. has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for JMT-206 for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.
The priority BLA from Otsuka Pharmaceutical Co. Ltd., of Tokyo, and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization Inc., for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN) has received accelerated approved by the U.S. FDA.
A disrupted balance between T-effector and T-regulatory cells, together with the activation of autoreactive or alloreactive B cells that generate pathogenic antibodies, is a defining feature of autoimmune diseases and transplant rejection and contributes to their often poor outcomes.
Invivyd Inc. has nominated VBY-329 as a preclinical development candidate for the prevention of respiratory syncytial virus (RSV) among neonates, infants and children.
Mabloc LLC has established a strategic partnership with Instituto Butantan to co-develop and manufacture MBL-YFV-01, a monoclonal antibody therapy for yellow fever virus (YFV) infection, including emergency post-exposure use.
Bluejay Therapeutics Inc.’s lead compound, the fully human monoclonal antibody brelovitug (BJT-778), produced positive virologic response data in the company’s phase II study of chronic hepatitis D virus, a condition with no approved treatment in the U.S.
RSS
